Zafgen, Inc. Announces Participation at BIO 2009 International Convention
CAMBRIDGE, Mass., May 14, 2009 – Zafgen, Inc., a private venture-backed
biopharmaceutical company focused on developing novel obesity therapeutics, today announced
that Thomas Hughes, Ph.D., president and chief executive officer has been selected to participate
on a panel at the BIO 2009 International Convention on Tuesday, May 19, 2009 at 5:00 p.m.
(EDT) at the Georgia World Congress Center in Building A, Level 4.
The session, titled “Industry is from Mars, Academia from Venus,” will focus on creating
effective and productive cooperation between companies and academic institutions. Participants
will discuss the opportunities and challenges of managing such partnerships.
“I am looking forward to participating in this session at BIO and discussing the unique
opportunities and challenges that both parties face in collaborations between industry and
academia,” stated Dr. Hughes. “Both at Zafgen and in my prior work at the Novartis Institutes
for BioMedical Research leading drug discovery research on type 2 diabetes, I’ve been integrally
involved in these kinds of partnerships, which can be mutually beneficial to both public and
private organizations. At Zafgen, the success of our virtual business model relies on vibrant and
productive collaborations. We have a strong portfolio of research agreements and contracts in
place to advance Zafgen’s development efforts and to further our scientific understanding of the
central role played by adipose tissue in obesity.”
About Zafgen, Inc.
Zafgen is the first biopharmaceutical company dedicated to developing novel obesity
therapeutics that directly target and shrink fat tissue to help the body regain and sustain a lean,
healthy state. Adipose tissue (fat) is composed primarily of cells that store unused calories, as
well as an extensive network of blood vessels that support the tissue. The nature of the tissue
and the interplay between fat cells and the supporting blood vessels play a critical and active role
in determining the overall size of the fat tissue, and therefore, an individual’s weight. Zafgen’s
groundbreaking approach targets obesity at its root cause by safely manipulating and shrinking
the blood supply to fat tissue, driving the loss of fat and a return to a more healthy body weight.
Zafgen's leadership and scientific advisors include the leading experts in obesity, metabolic disorders
and medicinal chemistry. Founded in 2005, the company is located in Cambridge,
Massachusetts. For more information, visit www.zafgen.com.